U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Javier Revollo
  1. Science & Research (NCTR)

Javier Revollo Ph.D.

Staff Fellow — Division of Genetic and Molecular Toxicology

Javier Revollo
Javier Revollo, Ph.D.

(870) 543-7391
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page


About  |  Publications  |  Lab Member


Background

Dr. Javier Revollo received a B.S. degree in genetics from the University of Wisconsin-Madison in 2000 and a Ph.D. from Washington University in St. Louis in 2006. He pursued postdoctoral studies at the National Institutes of Health (NIH) between 2007 and 2012. He joined FDA as a commissioner’s fellow in 2012. During his career, Dr. Revollo has studied several biomedical phenomena, including parasitology, NAD biosynthesis, mammalian aging, and glucocorticoid signaling. He has received numerous awards, including:

  • “Fellows Award for Research Excellence” (NIH, 2010)
  • “Rodbell Research Award” (NIH, 2010)
  • “Presidential Award” from The Endocrine Society in 2011.

Dr. Revollo was recruited to FDA because of his expertise in mammalian genetics and next generation sequencing (NGS).

Research Interests

The flow cytometry-based Pig-a assay detects cells deficient in Glycosylphosphatidylinositol (or GPI)-anchored surface markers and provides a rapid and cost-effective enumeration of cells that are presumed to contain mutations in the endogenous X-linked Pig-a gene. Dr. Revollo is currently working on the validation of the Pig-a assay by genetically characterizing presumed Pig-a mutants derived from the assay.

Another research area that interests Dr. Revollo is the direct detection of somatic mutations. Somatic mutations are genetic alterations in cells that increase cancer risk. They can occur spontaneously but also result from DNA damage induced by the environment (e.g., sunlight) or genotoxic compounds (e.g, carcinogens). Current genetic toxicology assays can only estimate somatic-mutation rates by assaying the function of certain gene markers (e.g., Pig-a) or transgenes. Dr. Revollo is developing NGS methods capable of directly and efficiently identifying somatic mutations in the whole genome — in any tissue, and in any species, or any established cell culture — without the need for selecting and expanding cells that have mutations in only a few specific reporter genes.

Professional Societies/National and International Groups

Environmental Mutagen and Genomics Society
Member
2014 – 2016

Applied Technologies Session Chair
2014

Transgenic and In Vivo Mutagenesis Special Interest Group New Investigator Co-chair
Current

Hispanic Organization of Toxicologists
Member
2016

Society for Advancement of Hispanics/Chicanos and Native Americans in Science
Member
2010 – 2012

BACK TO TOP

Selected Publications

Whole Genome Sequencing of Mouse Lymphoma L5178Y-3.7.2C (TK+/-) Reveals Millions of Mutations and Genetic Markers.
McKinzie PB, Revollo JR.
Mutat Res Genet Toxicol Environ Mutagen. Under Review.
[Text Abstract on PubMed]

Mutation Analysis with Random DNA Identifiers (MARDI) Catalogs Pig-A Mutations in Heterogeneous Pools of CD48-Deficient T Cells Derived from DMBA-Treated Rats.
Revollo JR, Crabtree NM, Pearce MG, Pacheco-Martinez MM, Dobrovolsky VN.
Environ Mol Mutagen. 2016 Mar; 57(2):114-24.
[Text Abstract on PubMed]

Whole Genome and Normalized mRNA Sequencing Reveal Genetic Status of TK6, WTK1, and NH32 Human B-Lymphoblastoid Cell Lines.
Revollo J, Petibone DM, McKinzie P, Knox B, Morris SM, Ning B, Dobrovolsky VN.
Mutat Res Genet Toxicol Environ Mutagen. 2016 Jan 1; 795:60-9.
[Text Abstract on PubMed]

CD48-Deficient T-Lymphocytes from DMBA-Treated Rats have De Novo Mutations in the Endogenous Pig-A Gene.
Dobrovolsky VN, Revollo J, Pearce MG, Pacheco-Martinez MM, Lin H.
Environ Mol Mutagen. 2015 Oct; 56(8):674-83.
[Text Abstract on PubMed]
 
Confirmation of Pig-A Mutation in Flow Cytometry-Identified CD48-Deficient T-Lymphocytes from F344 Rats.
Revollo J, Pearce MG, Petibone DM, Mittelstaedt RA, Dobrovolsky VN.
Mutagenesis. 2015 May; 30(3):315-24.
[Text Abstract on PubMed]

Draft Genome Sequence of a Methicillin-Resistant Staphylococcus Aureus ST1413 Strain for Studying Genetic Mechanisms of Antibiotic Resistance.
Marasa BS, Revollo J, Iram S, Sung K, Xu J, Khan S.
Genome Announc. 2014 Mar 6; 2(2). pii:e00162-14.
[Text Abstract on PubMed]

HES1 is a Master Regulator of Glucocorticoid Receptor-Dependent Gene Expression.
Revollo JR, Oakley RH, Lu NZ, Kadmiel M, Gandhavadi M, Cidlowski JA.
Sci Signal. 2013 Dec 3; 6(304):ra103.
[Text Abstract on PubMed]

The Ways and Means that Fine Tune Sirt1 Activity.
Revollo JR, Li X.
Trends Biochem Sci. 2013 Mar; 38(3):160-7.
[Text Abstract on PubMed]

Glucocorticoids Regulate Arrestin Gene Expression and Redirect the Signaling Profile of G Protein-Coupled Receptors.
Oakley RH, Revollo J, Cidlowski JA.
Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):17591-6.
[Text Abstract on PubMed]

Mechanisms Generating Diversity In Glucocorticoid Receptor Signaling.
Revollo JR, Cidlowski JA.
Ann N Y Acad Sci. 2009 Oct; 1179:167-78.
[Text Abstract on PubMed]

Nampt/PBEF/Visfatin Regulates Insulin Secretion in Beta Cells as a Systemic NAD Biosynthetic Enzyme.
Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S.
Cell Metab. 2007 Nov; 6(5):363-75.
[Text Abstract on PubMed]

The Regulation of Nicotinamide Adenine Dinucleotide Biosynthesis by Nampt/PBEF/Visfatin in Mammals.
Revollo JR, Grimm AA, Imai S.
Curr Opin Gastroenterol. 2007 Mar; 23(2):164-70.
[Text Abstract on PubMed]

Structure of Nampt/PBEF/Visfatin, a Mammalian NAD+ Biosynthetic Enzyme.
Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C.
Nat Struct Mol Biol. 2006 Jul; 13(7):661-2.
[Text Abstract on PubMed]

The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells.
Revollo JR, Grimm AA, Imai S.
J Biol Chem. 2004 Dec 3; 279(49):50754-63.
[Text Abstract on PubMed]

Sphingolipids are Essential for Differentiation but not Growth in Leishmania.
Zhang K, Showalter M, Revollo J, Hsu FF, Turk J, Beverley SM.
EMBO J. 2003 Nov 17; 22(22):6016-26.
[Text Abstract on PubMed]

BACK TO TOP

Lab Member

Lea Patrice McDaniel, M.S.
Biologist
(870) 543-7391
NCTRResearch@fda.hhs.gov  

BACK TO TOP


Contact Information
Javier Revollo
(870) 543-7391
Expertise
Expertise
Approach
Domain
Technology & Discipline
Toxicology